However, for patients with PD‐L1 expression >50% on tumor cells, first‐line treatment with a PD‐1 or PD‐L1 inhibitor in combination with chemotherapy has been shown to significantly enhance response rates and improve survival, likely due to the immunogenic effects of cytotoxic agents [55, 56, 57, 58, 59]. This evidence concerns the gene CD274 and neoplasm.